NewsBenzingaCava Stock Tanks on Q3 Double-Miss: CEO Points to 'Broader Industry Pressures' **Cava crolla in borsa dopo un doppio mancato obiettivo nel terzo trimestre: il CEO cita “pressioni più ampie del settore”** Cava Stock Tanks on Q3 Double-Miss: CEO Points to 'Broader Industry Pressures' **Cava crolla in borsa dopo un doppio mancato obiettivo nel terzo trimestre: il CEO cita “pressioni più ampie del settore”** Benzinga 2026.11.04 22:12 (GMT+0) Open on Benzinga Other news ConocoPhillips Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Reported Earlier, Comstock Resources Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $384.363M Miss $424.364M Estimate Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Reported Earlier, Gold Royalty Q3 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $10.246M Beat $8.235M Estimate Bithumb to Delist Fetch.ai (FET) on December 7 Sony Group Q2 EPS ¥76.48, Sales ¥3.429T
ConocoPhillips Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Reported Earlier, Comstock Resources Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $384.363M Miss $424.364M Estimate
Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval
Reported Earlier, Gold Royalty Q3 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $10.246M Beat $8.235M Estimate
